Peptide vaccine to prevent relapse in acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a personalized vaccine that aims to train your immune system to fight any remaining leukemia cells. It is for people with AML who are in remission but are not candidates for a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of acute myeloid leukemia (AML).
- Your leukemia must be in remission (either full or with slight remaining disease after chemo).
- You must not be eligible for a stem cell transplant.
- You should be fairly active and able to care for yourself (ECOG score of 0-2).
- Your liver, kidney, and blood counts must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine, alone or with an immunotherapy drug called toripalimab, to help keep acute myeloid leukemia (AML) in remission. It is for people who have finished initial treatment, are in remission, but still have some leukemia cells remaining (MRD positive) and have a specific NPM1 gene mutation.
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
This trial tests a new treatment called NCR300 to see if it can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It may help people who are at high risk of relapse.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Hear when a new Acute Myeloid Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.